This week on the podcast Agustin talks recent macroeconomic trends and their implications on the stock market and biotech specifically, highlights the positive phase 3 data for another Biogen Alzheimer's drug, and shares the recent approval for Amylyx Pharmaceuticals and their 6-figure a year drug for ALS. 

All Business. No Boundaries.
Welcome to All Business. No Boundaries, a collection of supply chain stories by DHL...

Listen on: Apple Podcasts   Spotify

If you are a fan of this show make sure to like, comment, subscribe and follow me on Twitter @biotech_bros. If you have any questions regarding the product offerings feel free to explore my website biotechbros.com